Local view for "http://purl.org/linkedpolitics/eu/plenary/1999-12-15-Speech-3-124"
Predicate | Value (sorted: default) |
---|---|
rdf:type | |
dcterms:Date | |
dcterms:Is Part Of | |
dcterms:Language | |
lpv:document identification number |
"en.19991215.6.3-124"2
|
lpv:hasSubsequent | |
lpv:speaker | |
lpv:spokenAs | |
lpv:translated text |
"Mr President, the Grossetête report on orphan medicinal products responds to an important requirement. It is to be congratulated for providing an immediate although imperfect solution to this problem.
The absence of proper research into these supposedly rare diseases is prejudicial to thousands of patients.
However, this report has several shortcomings. Firstly, it takes into account only private research and research carried out by the pharmaceutical industry, as if only these were capable of finding therapies to research medicinal products. No support is given to public research or to non-profit-making bodies which may also be capable of finding therapies.
The second and most important shortcoming is that, although mentioned in the preamble, the text does not provide a solution for one vital problem. This involves research into diseases which are common but for which there is no market for the pharmaceutical industry, in particular diseases affecting people who cannot pay for their treatment. This is particularly the case with tropical diseases and even malaria and tuberculosis.
No incentives for research into these diseases and no regulations are suggested which is astounding in view of the millions of deaths caused by these diseases. Parliament and the Commission must consider this issue in the coming months because the lives of millions of people are just as important as the profit of a few businesses."@en1
|
Named graphs describing this resource:
The resource appears as object in 2 triples